Energy innovation expert, Barbara Burger, shares how she sees the future of energy playing out as a dance between mice — the startups — and elephants — the incumbent corporations. Photo via Getty Images

There is so much good to say about the state of innovation toward a lower carbon future. All the necessary ingredients seem to be here – passionate, committed and incredibly sharp innovators, capital support from seed to growth, incumbent corporations that are looking to decarbonize their base businesses and build new ones, and government agencies that have developed the incentives and programs that are needed to help navigate over the traditional valleys of death.

Why then is this so hard?

I spend a lot of my time now listening and learning from the startups (the mice) and the incumbent corporations (the elephant) and then looking for ways to help them better collaborate.

The questions I frequently get asked from both sides reflect the different worlds they live in. Many mice don’t know who to engage within the elephants — or, more importantly, how to engage with them. Nor is it often clear what the elephant might want to get out of a collaboration. Many elephants envision collaboration with startups at the conceptual level but don’t know how best to find the most promising ones nor what to do once they locate a promising one. There could likely be an entire book on the dance but for this article, let’s focus on the very early part of the dance.

Let’s assume that some early diligence has been done on one or both sides. Of course, we all know that most relationships start by one party pursuing the other (rather than some magical meeting at the center of the dance floor). Knowing the why for both parties is one of the best starts. Here’s some questions that might help with this.

For the startup, are you looking for validation of your technology solution, investment, pilots, customers, a development partner, a commercial or operating partner, an ultimate exit, or maybe all of the above? What stage of development are you at? This collaboration is key to your success; how important is it to the elephant’s success? Would your tech live outside of their fence line or within? The answers to these questions can help pinpoint where in the elephant you want to target for your initial discussions as well as start to figure out the elephant’s why.

For the incumbant corporation, are you looking for potential solutions to problems in your base business? Possible new businesses? Understanding of the landscape with a view on both threats and opportunities? How important is this problem to solve in the priorities of your company? How does the startup’s problem definition align with one that your company wants to address? What is your experience with trialing new technology? Are you okay with a startup that is backed by one of your competitors? How easily will it be to make the argument internally to get resources to deepen a relationship? If, given the go ahead internally, do you have team members that have the time and capability to collaborate with the startup? Are you willing to have it known that you are collaborating with the startup?

There are lots of questions here and the why is often an iterative journey for both sides. It is as much mindset, influence, strategy, champions, and risk tolerance at individual levels as it about technology and economics.

Let’s hope these questions get you out on the dance floor with a promising partner.

------

Barbara J. Burger is a startup adviser and mentor and serves on the board of directors for Greentown Labs. She previously led corporate innovation for two decades at Chevron.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.